Newsroom

News

Many SARS-coronavirus-2 infections are mild or completely asymptomatic and are therefore not detected. This makes it difficult to assess pandemic trends, prevention strategies and mortality rates. Antibody studies can provide reliable information on what percentage of the population has already been infected with SARS-CoV-2. In a nationwide study, the Helmholtz Centre for Infection Research (HZI) in Braunschweig is using regional samples to investigate the spread of antibodies against the novel coronavirus. The study examines about 3000 test persons in the urban region of Aachen from 9th September 2020.

09.09.2020

HZI Campus

News

The European Research Council (ERC) awards three scientists from the Helmholtz Centre for Infection Research (HZI) with an ERC Starting Grant. The grants of up to 1.5 million Euros over a period of five years will be awarded to Jun Prof Neva Caliskan from the Helmholtz Institute for RNA-based Infection Research (HIRI), Jun Prof Gregor Fuhrmann from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Prof Yang Li from the Centre for Individualised Infection Medicine (CiiM).

03.09.2020

HZI Campus

CiiM

HIPS

HIRI

News

Bacteria show a wide range of capabilities in withstanding antibiotic treatment or attack by our immune system, which are great challenges in infection research. Scientists at the Würzburg-based Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the Helmholtz Centre for Infection Research (HZI), have developed a novel approach to reading the activity of hundreds of genes in an individual bacterium by sequencing its RNA. This groundbreaking work was just published in the journal Nature Microbiology. Using bacterial single-cell RNA sequencing it might be possible to elucidate the tricks bacteria use to develop resistance and close these loopholes with tailored drugs.

18.08.2020

HIRI

News

The new consortium CARE (Corona Accelerated R&D in Europe), supported by the Innovative Medicines Initiative (IMI) public-private partnership, announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totalling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG (Zurich, Switzerland). It integrates partners’ COVID-19 projects ongoing since February 2020.

18.08.2020

HZI Campus

3D-Darstellung von Coronavirus-Partikeln

News

Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and inhibition. Experts from Charité – Universitätsmedizin Berlin, the University of Bonn, the German Center for Neurodegenerative Diseases (DZNE), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF), along with colleagues from a nationwide research network, present these findings in the scientific journal Cell.

06.08.2020

CiiM

HIRI

News

Who has overcome an infection with the virus without noticing, and how many people have already produced protective antibodies against the new coronavirus? Various antibody studies are now under way that will provide information on immunity or seroprevalence in the population. However, in order to compare these studies in a timely and reliable manner and provide a comprehensive evaluation, the German Center for Infection Research (DZIF) is building a platform that gathers the methodology and results of the tests and makes the data available to interested researchers. The project “LEOSS.sero-survey” will be led by scientists at the Helmholtz Centre for Infection Research (HZI) and implemented in collaboration with Helmholtz Federated IT Services (HIFIS).

03.08.2020

HZI Campus

Back to the first page
...
59
60
61
62
...
148

HZI in the media

... Forschungsschwerpunkt „Neue Antiinfektiva“ des Helmholtz-Zentrums für Infektionsforschung (HZI) entwickeln fast 20 Forschungsgruppen neue ...

18.11.2025

Regional Heute

... , Stellvertretende Teamleiterin der Klinischen Epidemiologie am Helmholtz-Zentrum für Infektionsforschung (HZI), Braunschweig.

17.11.2025

Biermann Medizin

... und individueller Darmflora ab.

Forscher am Helmholtz-Zentrum für Infektionsforschung arbeiten bereits an der nächsten Generation ...

14.11.2025

Ad Hoc News

Klett-Tammen, Abteilung Epidemiologie (EPID), Helmholtz-Zentrum für Infektionsforschung (

HZI

), Braunschweig. Grundsätzlich sei auch die ...

13.11.2025

Deutsches Ärzteblatt

von Angios in Innsbruck & wissenschaftlicher Geschäftsführer Helmholtz-Zentrum für Infektionsforschung in Braunschweig/Deutschland), Klaus

13.11.2025

meinbezirk.at

... zu adressieren, suchen Forschende am HZI-Standort Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) im Rahmen ...

13.11.2025

Prophylaxe Journal

new antiviral medicines, says virologist Christian Sieben of the Helmholtz Centre for Infection Research in Germany.

Earlier in 2025, for

10.11.2025

The Press

Hochschule Hannover, die Universitätsmedizin Göttingen, das Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die KI-

07.11.2025

Heise online

... , Leiter der Forschungsgruppe Mikrobielle Wirkstoffe am Helmholtz-Zentrum für Infektionsforschung, zu bedenken. Das erste ...

07.11.2025

Leipziger Volkszeitung (LVZ)

Quelle: Pressemitteilung

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025

LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025

Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025

Augsburger Allgemeine

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.